What are impacts of SK and Hanmi’s ‘low-volume Xarelto generic’ approvals?

SK Chemicals and Hanmi Pharm which succeeded in developing the first generics of the novel oral anticoagulant(NOAC), Xarelto, acquired the low volume and entire volumes respectively.

Particularly, since the two companies were confirmed to apply the minimum volume, 2.5mg, for the ‘prioritized sales right,’ the 9-month exclusive right of generic market, impacts on the market will not be signific...